1例前列腺癌患者随访10年报道及文献复习  

10-year follow-up of a patient with prostate cancer:Case report and literature review

作　　者：胡恩平[1] 潘正波[1] 季广华 师冠云 Hu Enping;Pan Zhengbo;Ji Guanghua;Shi Guanyun(Department of Urology,Taizhou Municipal Hospital,Taizhou 318000,China)

机构地区：[1]台州市立医院泌尿外科,台州318000

出　　处：《微创泌尿外科杂志》2022年第2期112-116,共5页Journal of Minimally Invasive Urology

摘　　要：目的:探究1例盆腔淋巴结转移高危前列腺癌患者联合根治术、术前辅助及术后辅助内分泌治疗后的临床疗效。方法:回顾性分析1例盆腔淋巴结转移高危前列腺癌患者,经术前辅助内分泌治疗、前列腺癌根治术、术后辅助内分泌治疗,7年后进展为去势抵抗前列腺癌,后改用阿比特龙联合泼尼松/地塞米松治疗,并随访PSA、临床症状体征及不良反应。结果:术后辅助内分泌治疗维持87个月至mCRPC,阿比特龙治疗25个月至耐药,患者临床无症状生存10年,一般状况良好。结论:盆腔淋巴结转移高危前列腺癌患者或可从以根治术为基础的术前、术后辅助内分泌治疗中增加生存获益,延缓进展至mCRPC。Objective:To explore the clinical effect of combined radical prostatectomy,neoadjuvant therapy and adjuvant endocrine therapy in 1 case of high-risk prostate cancer with pelvic lymph node metastasis.Methods:A case of high-risk prostate cancer with pelvic lymph node metastasis was analyzed retrospectively.After 7 years of sequential neoadjuvant endocrine therapy,radical prostatectomy and adjuvant endocrine therapy,it developed castration resistance to prostate cancer(CRPC).It was treated with abiraterone combined with prednisone/dexamethasone.PSA,clinical symptoms,signs,and adverse reactions were followed up.Results:Postoperative adjuvant endocrine therapy was maintained from 87 months to metastatic CRPC(mCRPC)and abiraterone treatment from 25 months to drug resistance.The patients survived asymptomatic for 10 years and had good physical fitness.Conclusion:Patients with prostate cancer at high risk of pelvic lymph node metastasis may be able to delay progression to mCRPC from neoadjuvant,adjuvant endocrine therapy based on radical surgery.The new endocrine therapy can increase the benefit of clinical asymptomatic survival.

关 键 词：淋巴结转移 根治术 内分泌治疗 转移去势抵抗性前列腺癌 

分 类 号：R737.25[医药卫生—肿瘤]